Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Hasılat
1,007
940
747
801
702
498
Hasılat Artışı (YoY)
18%
26%
-7%
14%
41%
38%
Satınalma Maliyeti
470
450
380
388
326
238
Brüt Kâr
536
489
367
413
376
260
Satış, Genel ve İdari
426
389
352
335
261
204
Araştırma ve Geliştirme
196
198
169
170
92
63
İşletme Giderleri
623
588
522
505
353
268
Diğer Finansman Gelirleri (Giderleri)
--
--
--
--
--
--
Kâr Öncesi Gelir
-204
-91
-220
-92
15
-36
Kira Vergisi Gideri
-1
4
2
1
0
-1
Net Kâr
-203
-96
-222
-94
15
-34
Net Income Growth
Kâr Artışı
61%
-56.99%
136%
-727%
-144%
42%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
67.65
65.45
64.96
64.1
64.3
61
Hisse Değişimi (Yıllık Üst Üste)
3%
1%
1%
0%
5%
4%
EPS (Diluted)
-3
-1.46
-3.42
-1.47
0.24
-0.56
EPS Artışı
55%
-56.99%
133%
-713%
-143%
33%
Öz sermaye akışı
-71
-41
-83
7
87
-7
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
53.22%
52.02%
49.12%
51.56%
53.56%
52.2%
Faaliyet Kâr Marjı
-8.54%
-10.53%
-20.61%
-11.48%
3.13%
-1.6%
Kâr Marjı
-20.15%
-10.21%
-29.71%
-11.73%
2.13%
-6.82%
Özsermaye Karlılık Oranı
-7.05%
-4.36%
-11.11%
0.87%
12.39%
-1.4%
EBITDA
-69
-83
-139
-78
35
2
EBITDA Marjinali
-6.85%
-8.82%
-18.6%
-9.73%
4.98%
0.4%
D&A EBITDA için
17
16
15
14
13
10
Faaliyet Kârı
-86
-99
-154
-92
22
-8
Faaliyet Kâr Marjı
-8.54%
-10.53%
-20.61%
-11.48%
3.13%
-1.6%
Verilen Vergi Oranı
0.49%
-4.39%
-0.9%
-1.08%
0%
2.77%
Önemli İstatistikler
Önceki Kapanış
$18.69
Açılış fiyatı
$18.95
Günün Aralığı
$18.49 - $19.49
52 haftalık aralık
$9.98 - $37.71
İşlem hacmi
753.1K
Ort.Hacim
1.8M
EPS (TTM)
-3.49
Dividend yield
--
Piyasa Değeri
$1.2B
TNDM nedir?
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,650 full-time employees. The company went IPO on 2013-11-13. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.